Stocks Health care PBM
NASDAQ · Health carePsyence Biomedical Ltd. (PBM)
In fiscal 2025 capital spending exceeded operating cash flow by $3.7M. At March 31, 2025 it held $6.1M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on June 22, 2026.
Key facts about Psyence Biomedical Ltd.
- Net worth
- Psyence Biomedical Ltd. has a market value (market cap) of $11.9M at the latest share price, and shareholders' equity of $6.7M on its balance sheet at March 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $3.7M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on June 22, 2026 and covers the period to March 31, 2026. Open on SEC EDGAR
What Psyence Biomedical Ltd. does
Psyence Biomedical Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | $1M | $5.24 | -$3.7M |
| 2024 | n/a | -$51.2M | -$4,674.25 | -$3M |
| 2024 | n/a | -$3.2M | -$394.06 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Psyence Biomedical Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Passive stake (5% or more) SCHEDULE 13G
- October 5, 2026
- September 28, 2026
- September 23, 2026
- September 14, 2026
- August 26, 2026
- August 26, 2026Form F-3 filing F-3
- August 6, 2026
- June 22, 2026Annual report (foreign issuer) 20-F · period to March 31, 2026
- June 10, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Psyence Biomedical Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns PBM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Psyence Labs Ltd.13D, may seek influence | 30.05% | June 3, 2026 |
| Frederick V. Fortmiller, Jr.13G, passive with 5 related filers | 9.95% | November 12, 2024 |
| AdvisorShares Trust13G, passive | 6.78% | October 5, 2026 |
Largest institutional holders
Insiders
Questions about PBM
What does Psyence Biomedical Ltd. do?
Psyence Biomedical Ltd. is a company in the Health care sector, listed on NASDAQ as PBM. Its shares trade on NASDAQ under the ticker PBM.
What is Psyence Biomedical Ltd.'s net worth?
Psyence Biomedical Ltd. has a market value (market cap) of $11.9M at the latest share price, and shareholders' equity of $6.7M on its balance sheet at March 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Psyence Biomedical Ltd. profitable?
Yes. In fiscal 2025 it reported net income of $1M.
When did Psyence Biomedical Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on June 22, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 5, 2026.
Similar companies
Compare PBM with
Follow PBM
Get an email when Psyence Biomedical Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Psyence Biomedical Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.